Ads
related to: johnson & johnson- Latest news
See the latest news from J&J.
Company updates and more.
- Our leadership team
Meet the J&J Executive Committee
& our Board of Directors.
- Discover J&J
Learn about our strength
in healthcare innovation.
- The J&J Credo
Putting the needs of the
people we serve first.
- Latest news
Search results
South Africa regulator finds no toxin in recalled cough syrup
Reuters via Yahoo News· 1 day agoJOHANNESBURG (Reuters) -An investigation into two recalled batches of children's cough syrup made in South Africa by Johnson & Johnson found no trace of ...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Tri-County Times· 6 days ago(PRNewsfoto/Johnson & Johnson)
Novavax's stock surges almost 300% in the past month
Yahoo Finance· 1 hour agoIt missed out on the COVID-19 vaccine windfall that the mRNA vaccine makers, and to some degree Johnson & Johnson (JNJ) with its less efficacious vaccine...
The Potential Rise in the Price of Johnson & Johnson
Knox Daily· 3 days agoIn a filing, Johnson & Johnson revealed its EVP, Global Corp Affairs Broadhurst Vanessa unloaded Company’s shares for reported $1.44 million on Mar 13 ’ ...
Dallas Firm That Won $45M Talc Verdict Scored Again: Jury Hits J&J With $260M | Law.com
Law.com· 2 days agoThe Dallas plaintiffs’ firm that won a $45 million talc verdict against Johnson & Johnson scored a...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Valley City Times Record· 6 days agoJohnson & Johnson today announced new data from the Phase 3 MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVANT® (amivantamab-vmjw ...
Osteal raises $50m to bring joint infection drug/device combo to market
Medical Device Network via Yahoo Finance· 10 hours agoMedtech giant Zimmer Biomet led the round with participation from existing investors, including ...
Talc Plaintiffs Move to Quash Subpoenas as J&J Defends Attorney's Conduct | Law.com
Law.com· 6 days agoThe fight between Johnson & Johnson and plaintiffs firm Beasley Allen escalated this week with...
Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib...
Valley City Times Record· 3 days agoJohnson & Johnson announced today new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
WPRI Providence· 6 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients ...
Ad
related to: johnson & johnson